GSK's Strong Performance: Why I'm Upgrading To 'Strong Buy'

Core Viewpoint - GSK's fourth quarter 2024 financial results were released on February 5, showing a mixed market reaction primarily due to the underperformance of its vaccine franchise [1] Financial Performance - GSK reported its financial results for the fourth quarter of 2024, which were characterized by a relatively weak performance in its vaccine segment [1]